Regeneron Pharmaceuticals Inc
REGN Real Time Price USDRecent trades of REGN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in REGN holdings by institutional investors
Quarterly net insider trading by REGN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$610,000 Jan 20, 2026 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
-
$570,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$610,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$400,000 Apr 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
-
$400,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jan 20, 2022 Issue: None
-
$360,000 Oct 20, 2021 Issue: None
-
$310,000 Jul 20, 2021 Issue: None
-
$330,000 Apr 20, 2021 Issue: None
-
$330,000 Jan 21, 2021 Issue: None
-
$480,000 Oct 20, 2020 Issue: None
-
$320,000 Jul 20, 2020 Issue: None
-
$370,000 Apr 20, 2020 Issue: None
-
$340,000 Jan 21, 2020 Issue: None
-
$180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
-
$240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$130,000 Oct 20, 2016 Issue: Health Issues
-
$120,000 Jul 20, 2016 Issue: Health Issues
-
$50,000 Apr 19, 2016 Issue: Health Issues
-
$50,000 Jan 16, 2016 Issue: Health Issues
-
$50,000 Oct 20, 2015 Issue: Health Issues
-
$50,000 Jul 20, 2015 Issue: Health Issues
-
$60,000 Apr 20, 2015 Issue: Health Issues
-
$52,000 Jan 19, 2015 Issue: Health Issues
-
$50,000 Oct 20, 2014 Issue: Health Issues
-
$50,000 Jul 21, 2014 Issue: Health Issues
-
$50,000 Jan 22, 2014 Issue: Health Issues
-
$50,000 Oct 21, 2013 Issue: Health Issues
-
$40,000 Jul 22, 2013 Issue: Health Issues
-
$30,000 Apr 24, 2013 Issue: Health Issues
-
$30,000 Feb 02, 2013 Issue: Health Issues
-
$30,000 Oct 31, 2012 Issue: Health Issues
REGN Estimated quarterly lobbying spending
REGN Revenue by Segment or Geography
New REGN patent grants
-
Patent Title: Detection assays for coronavirus neutralizing antibodies Jan. 20, 2026
-
Patent Title: Transcription modulation in animals using crispr/cas systems Jan. 20, 2026
-
Patent Title: Compositions and methods for making antibodies based on use of expression-enhancing loci Jan. 20, 2026
-
Patent Title: Il2-based therapeutics and methods of use thereof Jan. 20, 2026
-
Patent Title: Modifying binding molecules to minimize pre-existing interactions Jan. 13, 2026
-
Patent Title: Il12 receptor agonists and methods of use thereof Jan. 13, 2026
-
Patent Title: Crispr and aav strategies for x-linked juvenile retinoschisis therapy Jan. 13, 2026
-
Patent Title: Monitoring polysorbate hydrolysis in pharmaceutical formulations using an ultrasensitive extraction-free fatty acid quantitation method Jan. 06, 2026
-
Patent Title: Methods and systems for manufacturing viral vectors Jan. 06, 2026
-
Patent Title: Methods and compositions for sensitization of tumor cells to immune therapy Jan. 06, 2026
-
Patent Title: Dimerizing agent regulated immunoreceptor complexes Jan. 06, 2026
-
Patent Title: Room temperature stable lyophilized protein Jan. 06, 2026
-
Patent Title: Devices and systems for chromatography column bed support management and related methods Dec. 30, 2025
-
Patent Title: Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors Dec. 30, 2025
-
Patent Title: Heavy chain constant regions with reduced binding to fc gamma receptors Dec. 30, 2025
-
Patent Title: Antibodies comprising chimeric constant domains Dec. 30, 2025
-
Patent Title: Compositions and methods for making antibodies based on use of an expression-enhancing locus Dec. 23, 2025
-
Patent Title: Methods for treating atopic dermatitis by administering an il-4r antagonist Dec. 23, 2025
-
Patent Title: Use of il-1 antagonists to treat gout Feb. 14, 2012
-
Patent Title: Vegf antagonist formulations Feb. 07, 2012
-
Patent Title: High affinity human antibodies to human il-18 receptor Jan. 31, 2012
-
Patent Title: High-affinity human antibodies to human protease-activated receptor-2 Jan. 24, 2012
-
Patent Title: Nucleic acid molecules which encode human anti-cd20 antibodies and methods of use thereof Jan. 17, 2012
-
Patent Title: Vegf antagonist formulations for intravitreal administration Jan. 10, 2012
-
Patent Title: High affinity human antibodies to human il-4 receptor Jan. 10, 2012
-
Patent Title: Isolated nucleic acid molecules encoding a fusion protein capable of binding vegf Dec. 27, 2011
-
Patent Title: Method of treating rheumatoid arthritis with an il-6r antibody Dec. 20, 2011
-
Patent Title: High affinity human antibodies to human il-4 receptor Dec. 13, 2011
-
Patent Title: High affinity human antibodies to pcsk9 Nov. 22, 2011
-
Patent Title: Therapeutic methods for inhibiting tumor growth with combination of dll4 antagonists and vegf antagonists Nov. 01, 2011
-
Patent Title: Human antibodies to human il-6 receptor Oct. 25, 2011
-
Patent Title: Modified chimeric polypeptides with improved pharmacokinetic properties Oct. 04, 2011
-
Patent Title: High affinity human antibodies to human il-18 receptor Aug. 23, 2011
-
Patent Title: High affinity human antibodies to human nerve growth factor Aug. 02, 2011
-
Patent Title: Vegf-binding fusion proteins and therapeutic uses thereof Jul. 05, 2011
-
Patent Title: Nucleic acid molecule encoding a fusion polypeptide capable of binding vegf Jun. 21, 2011
-
Patent Title: Receptor based antagonists and methods of making and using Apr. 19, 2011
-
Patent Title: Human antibodies to human delta like ligand 4 Apr. 05, 2011
-
Patent Title: Human antibodies to human cd20 and method of using thereof Feb. 01, 2011
-
Patent Title: Method of increasing muscle mass with igf-1 fusion polypeptides Nov. 23, 2010
-
Patent Title: Use of il-1 antagonists to treat gout Oct. 26, 2010
-
Patent Title: Lyophilized vegf antagonist formulations for intravitreal administration Oct. 05, 2010
-
Patent Title: High affinity human antibodies to human il-4 receptor Sep. 14, 2010
-
Patent Title: Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof Aug. 24, 2010
-
Patent Title: Enhanced expression and stability regions Aug. 10, 2010
-
Patent Title: Interferon-α/β binding fusion proteins and therapeutic uses thereof Jun. 08, 2010
-
Patent Title: Methods of inhibiting ascites formation with modified chimeric vegf polypeptides Apr. 27, 2010
-
Patent Title: Monomeric self-associating fusion polypeptides and therapeutic uses thereof Feb. 23, 2010
-
Patent Title: Method for making homozygous genetic modifications Feb. 09, 2010
-
Patent Title: Stable liquid il-1 antagonist formulations Feb. 02, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to REGN from public contracts
Recent insights relating to REGN
Recent picks made for REGN stock on CNBC
ETFs with the largest estimated holdings in REGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $REGN stock a Buy, Sell, or Hold?
- What is the price target for $REGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $REGN stock?
- Who owns the most shares of $REGN stock?
- What funds own $REGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view REGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
- Address Tarrytown, NY
- Market Cap 82.5 billion
- Employees 15,410
- Industrial Classification Pharmaceutical Preparations
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|